- Home
- LIEN vs AQST Comparison
LIEN vs AQST Comparison
Compare LIEN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- AQST
- Stock Information
- Founded
- LIEN 2021
- AQST 2004
- Country
- LIEN United States
- AQST United States
- Employees
- LIEN N/A
- AQST N/A
- Industry
- LIEN
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- AQST Health Care
- Exchange
- LIEN NYSE
- AQST Nasdaq
- Market Cap
- LIEN 264.8M
- AQST 274.4M
- IPO Year
- LIEN 2022
- AQST 2018
- Fundamental
- Price
- LIEN $11.47
- AQST $2.75
- Analyst Decision
- LIEN
- AQST Strong Buy
- Analyst Count
- LIEN 0
- AQST 7
- Target Price
- LIEN N/A
- AQST $10.57
- AVG Volume (30 Days)
- LIEN 9.4K
- AQST 1.5M
- Earning Date
- LIEN 05-08-2025
- AQST 03-05-2025
- Dividend Yield
- LIEN 11.86%
- AQST N/A
- EPS Growth
- LIEN N/A
- AQST N/A
- EPS
- LIEN 0.67
- AQST N/A
- Revenue
- LIEN $12,681,914.00
- AQST $57,561,000.00
- Revenue This Year
- LIEN $71.81
- AQST N/A
- Revenue Next Year
- LIEN $113.93
- AQST $35.72
- P/E Ratio
- LIEN $17.20
- AQST N/A
- Revenue Growth
- LIEN 22.94
- AQST 13.80
- 52 Week Low
- LIEN $10.54
- AQST $2.24
- 52 Week High
- LIEN $13.38
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- AQST 45.85
- Support Level
- LIEN N/A
- AQST $2.45
- Resistance Level
- LIEN N/A
- AQST $2.91
- Average True Range (ATR)
- LIEN 0.00
- AQST 0.20
- MACD
- LIEN 0.00
- AQST 0.03
- Stochastic Oscillator
- LIEN 0.00
- AQST 49.18
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.